EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

Lufina Tsirizani iD, Hylke Waalewijn, Alexander Szubert iD, Veronica Mulenga, Chishala Chabala, Mutsa Bwakura-Dangarembizi, Moses Chitsamatanga, Diana A Rutebarika, Victor Musiime, Mariam Kasozi, Abbas Lugemwa, Helen M McIlleron iD und 6 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00771-25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Lufina Tsirizani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Ritonavir, Lopinavir, Atazanavir Sulfate, Darunavir. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership, Gilead Sciences, Janssen Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ritonavir is important in antiretroviral therapy (ART) because it is used to boost the drug exposure of its fellow protease inhibitors (PIs). While PIs are commonly used in children, ritonavir data in this population are quite scarce. We investigated the population pharmacokinetics of ritonavir given to boost exposures of lopinavir, atazanavir, or darunavir, and co-administered with nucleoside reverse transcriptase inhibitors (NRTIs) in African children, and investigated factors affecting its exposure. We conducted a pharmacokinetic sub-study within the CHAPAS-4 (ISRCTN22964075) trial, which randomized children to two NRTIs with twice-daily lopinavir/ritonavir, once-daily atazanavir/ritonavir, or once-daily darunavir/ritonavir, as second-line ART. Intensive pharmacokinetic blood samples were collected at week 6, and nonlinear mixed-effects modeling was used to identify factors affecting ritonavir pharmacokinetics. In all, 170 children were enrolled in the ritonavir-boosted PI arms of the CHAPAS-4 pharmacokinetic sub-study, with median age 10.6 (range 3.2–15.6) years and weight 26.0 (14.2–64.2) kg. Despite similar dose levels, ritonavir exposure varied widely depending on the companion PI. Compared to children on darunavir/ritonavir, those on atazanavir/ritonavir had 137% (95% CI 107%–190%) higher bioavailability and 20% (95% CI 11.3%–31.3%) faster clearance, while those on lopinavir/ritonavir had 23.4% (95% CI 8.20%–34.4%) lower bioavailability. No effect of NRTIs on ritonavir pharmacokinetics was observed. Ritonavir exposure is higher with atazanavir than with lopinavir or darunavir. These data provide greater insight into the use of ritonavir for boosting PIs in children and help reduce the knowledge gap regarding its exposure in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirLopinavirAtazanavir SulfateDarunavirHIV InfectionsHIV Protease InhibitorsAnti-HIV AgentsHumansMaleChildFemaleChild, PreschoolAdolescent

Stichwörter der Autor:innen

NONMEMpediatric antiretroviralpopulation pharmacokineticsprotease inhibitorsritonavir

Substanzen

RitonavirLopinavirAtazanavir SulfateDarunavirHIV Protease InhibitorsAnti-HIV Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Training and Research Unit of Excellence, Kamuzu University of Health Sciences, Blantyre, Malawi.
  • Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom.
  • Department of Paediatrics and Child Health, University of Zambia, School of Medicine, Lusaka, Zambia.
  • University Teaching Hospital, Lusaka, Zambia.
  • University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.

ORCID-Profile: Lufina Tsirizani, Alexander Szubert, Helen M McIlleron, Paolo Denti, Roeland E Wasmann

Förderung

  • European and Developing Countries Clinical Trials Partnership
  • Gilead Sciences
  • Janssen Pharmaceuticals
  • Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC)

Zitieren

APA

Tsirizani, L., Waalewijn, H., Szubert, A., Mulenga, V., Chabala, C., Bwakura-Dangarembizi, M., Chitsamatanga, M., Rutebarika, D. A., Musiime, V., Kasozi, M., Lugemwa, A., McIlleron, H. M., Burger, D. M., Gibb, D. M., Colbers, A., Denti, P., Wasmann, R. E., & CHAPAS-4 trial team (2025). Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00771-25

Vancouver

Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, et al. Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00771-25

BibTeX
@article{Tsirizani2025,
  author = {Tsirizani, Lufina and Waalewijn, Hylke and Szubert, Alexander and Mulenga, Veronica and Chabala, Chishala and Bwakura-Dangarembizi, Mutsa and Chitsamatanga, Moses and Rutebarika, Diana A and Musiime, Victor and Kasozi, Mariam and Lugemwa, Abbas and McIlleron, Helen M and Burger, David M and Gibb, Diana M and Colbers, Angela and Denti, Paolo and Wasmann, Roeland E and CHAPAS-4 trial team, CHAPAS-4 trial team},
  title = {Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00771-25}
}
Kostenlos starten →